Skip to content

YDES

YD Bio Ltd.

NASDAQ · Healthcare · Biotechnology · TW

$6.12
+3.38%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
—
EBIT
—
EPS
—
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
+30.6%
EBITDA
—
EBIT
—
Net income
—
EPS
+78.6%
Free cash flow
-69.3%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025